<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01186003</url>
  </required_header>
  <id_info>
    <org_study_id>10-0483</org_study_id>
    <nct_id>NCT01186003</nct_id>
  </id_info>
  <brief_title>Effectiveness of Adding Subcutaneous Long-Acting Detemir to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy</brief_title>
  <official_title>Effectiveness of a Subcutaneously Administered Long-Acting Insulin Detemir Added to Insulin Drip Therapy as Compared With Standard Insulin Drip Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators anticipate that the use of Detemir will decrease the duration of an insulin
      drip, the dose of short-acting insulin in the drip, hospital and ICU (intensive care unit)
      length of stay, improve glycemic control, and prevent rebound hyperglycemias when the insulin
      drip is discontinued.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2010</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in rebound hyperglycemia (blood glucose levels over 180 mg/dl)</measure>
    <time_frame>within 48 hours of discontinuation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in duration of insulin drip therapy and reduction in total and average per hour insulin drip dose</measure>
    <time_frame>within one week of insulin drip therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in ICU length of stay</measure>
    <time_frame>within two weeks of hospitalization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Equal or improved diabetes control</measure>
    <time_frame>within two weeks of hospitalization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in time to get back to control of glycemia (140-180 mg/dl) if rebound hyperglycemia occurs</measure>
    <time_frame>within one week post insulin drip</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Standard insulin drip therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin drip and Detemir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Detemir 0.25 units per kg body weight given subcutaneously every 24 hours while patients are receiving intravenous (IV) standard insulin drip therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Detemir</intervention_name>
    <description>Detemir 0.25 units per kg body weight given subcutaneously every 24 hours while patients are receiving intravenous (IV) standard insulin drip therapy</description>
    <arm_group_label>Insulin drip and Detemir</arm_group_label>
    <other_name>Levimir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetic ketoacidosis (DKA) and hyperosmolar non-ketotic states, hyperglycemia with
             severe illness, pre-and postoperative states, nothing by mouth (NPO), as well as
             gastric (tube feeding) and parenteral nutritional requiring insulin drip.

          -  Patients with type 1 and type 2 diabetes mellitus (DM) will be included.

          -  Patient with both types of diabetes will be among those treated with insulin drip
             while being NPO, having severe concomitant illness or receiving enteral and parenteral
             nutrition

          -  Patients will be of age 19 to 80.

        Exclusion Criteria:

          -  Inability to consent for the study for any reason including cognitive impairment
             secondary to hyperglycemia, presence of severe medical conditions requiring
             intubation, severe sepsis, hypothermia, and anticipated length of insulin drop 2 weeks
             and longer, pregnancy, Levemir allergy, and concurrent sulfonamide treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boris Draznin, MD., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2010</study_first_submitted>
  <study_first_submitted_qc>August 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2010</study_first_posted>
  <last_update_submitted>February 5, 2018</last_update_submitted>
  <last_update_submitted_qc>February 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Detemir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

